Deferred Tax Assets, Operating Loss Carryforwards in USD of Estrella Immunopharma, Inc. from Q3 2021 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Estrella Immunopharma, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and change rate from Q3 2021 to Q4 2024.
  • Estrella Immunopharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $2,425,707.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Estrella Immunopharma, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $2,425,707 31 Dec 2024 10-KT 25 Mar 2025 2024 FY
Q2 2024 $1,838,655 +$1,483,760 +418% 30 Jun 2024 10-KT 25 Mar 2025 2024 FY
Q2 2023 $354,895 +$197,698 +126% 30 Jun 2023 10-K 27 Sep 2024 2024 FY
Q4 2022 $0 -$52,021 -100% 31 Dec 2022 10-K 14 Mar 2023 2022 FY
Q3 2022 $229,618 +$206,115 +877% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $157,197 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $81,684 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $52,021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $23,503 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.